Overview FLUIDIA (acronym for bioFLUId for DIAgnostics) is developing a new multi-protein immunoassay (R/p-R test - Patent Pending) that allows to rapidly, quantitatively and cheaply measure the native and phosphorylated forms of Raf Kinase Inhibitor Protein (RKIP) in Serum / Plasma / Urine and any other biological sample. RKIP e p-RKIP are gaining more and more interest for the research community as they are truly implicated in the onset and progression of many tumors thus R/p-R test can help early diagnosis of many forms of cancer as lung / breast / colon and kidney cancer. In addition, research laboratories could use this test to measure the whole and phosphorylated form of the protein in any sample of interest in order to better characterise their functional role. The know-how acquired with the RKIP project is scalable to other protein biomarkers with similar characteristics. Additional patents are being filed for the protection of new method for the quantitative measurement of a number of modified proteins. Connected works: Papale M et Al. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget. 2017 Jun 20;8(25):40412-40424. doi: 10.18632/oncotarget.16341 https://www.ncbi.nlm.nih.gov/pubmed/?term=Papale+RKIP